Early Access — free while we kick the tires
EdgarHawk

Deep Track Biotechnology Master Fund, Ltd.

10% Owner

10% Owner
2 filings analyzed · 2 companies · Latest 2025-09-16

Companies

Company Buys Sells Direction
LB PHARMACEUTICALS INC LBRX 3 0 Net buying
DYNAVAX TECHNOLOGIES CORP DVAX 0 2 Net selling

Activity

September 2025
2025-09-16 LB PHARMACEUTICALS INC LBRX
high
Buy
2,666,666 shares
$39,999,990
Significance 7/10

Deep Track Biotech acquires 2,666,666 shares for $39,999,990.00 at $15.00; derivative conversion underway

Deep Track Biotechnology Master Fund, Ltd., a 10% owner, executed 2 separate purchases totaling 2,666,666 shares for $39,999,990.00 at $15.00 per share on 2025-09-12, the day of LBRX's recent listing (4 trading days prior to filing). This is a material capital commitment by a significant shareholder in a newly public company at its IPO reference price. The transaction is marked as a derivative-conversion event, meaning the insider's full position includes unreported derivative holdings in Form 4 Table II; the 666,666 shares showing post-transaction reflect only the converted equity portion, not the complete economic position. The cluster pattern shows 3 other insiders also acquired shares within the past 14 days, indicating broad insider appetite at current levels. Investors should monitor derivative position disclosures and track whether this cluster of acquisitions continues as LBRX trades post-listing.

August 2025
high
Sell
2,065,137 shares
$22,351,598
Significance 6/10

10% Owner Deep Track Biotech sells 2,065,137 shares (2.07M) for $22,351,598.19 across two days at $11.03–$10.59

Deep Track Biotechnology Master Fund, Ltd., a 10% holder, executed two separate sales totaling 2,065,137 shares for $22,351,598.19 at a blended average price of $10.82 on August 21–22, 2025, reducing its stake by 11.6% from 17,791,486 to 15,726,349 shares. The fund sold into a price environment where DVAX trades at $10.50 today, -27.1% from its 52-week high of $14.40, and the transaction prices of $11.03–$10.59 sat near the upper end of recent trading—marginally above current levels but below the recent high. Given DVAX's strong fundamentals (19.4% annual revenue growth, positive net income of $18.7M, and a market cap of $1.2B), the sale represents a material reduction in a major stakeholder's conviction, not a forced liquidation or structured plan execution that would suggest indifference to timing. The multi-day execution and substantial size ($22.4M) indicate a deliberate action by an informed holder managing a significant position.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access